http://www.clinpage.com/article/oracle_eyes_resurgence/C10 'WE'LL BE #1' Oracle Eyes Resurgence JANUARY 30, 2009 Comments Tell a Friend Print Tags: cro , eclinical , edc Whatever happened to Oracle Clinical, the database firm’s flagship application for clinical data management? It’s still there. As we noted a few days ago on this site, some Oracle customers in the sponsor and contract research organization (CRO) community are starting to acknowledge their usage of the company’s technology. But the company doesn’t make as much noise as its competitors. Some in the industry no longer believe they need a massive, central clinical data management system. In another key market, electronic data capture, Oracle’s technology has been outflanked by smaller, more agile companies that it must have formerly viewed as irksome tse-tse flies. Fair or not, the perception in the industry is that Oracle allowed Pfizer to drive the design of its EDC solution to such a degree that few other sponsor companies or CROs wanted anything to do with it. At the corporate level, the database firm has spent several years digesting $25 billion in acquisitions in a global race for size with Germany’s SAP . Even after that spree, Oracle is one of a select number of top-tier technology firms with a pristine financial profile. Just in case any other companies catch the eye of CEO, cofounder and yachtsman Larry Ellison, Oracle has $10.7 billion in cash in the bank. A Different Game Not long ago, Oracle’s Patti Devereux Gaves rang us up to explain that the company is hardly dozing. She’s based in Connecticut; her title is senior director of product strategy. Gaves says the health care and life sciences group at Oracle has been busily building for the future, and is not ceding any territory to any competitor on any front. “We’ll be #1 or #2 soon,” she says. “We’re not ruling anything out.” Gaves notes that the company already has most of the elements of an eclinical portfolio—including EDC, data management, safety, coding, data warehouse, clinical trial management—and is considering what to do about those it lacks. It sounds like buying, building and partnering to fill out its offerings are all under consideration. With time at Medidata and Pfizer under her belt, Gaves has a uniquely well-qualified background with which to pitch in on any Oracle effort to flex its muscles. One of her early jobs was with the database firm; she returned to the company in 2008 to help it chart a sort of re-entry to the still-thriving eclinical battlefield. At this point, at the end of the first decade of the 21st century, Gaves does not see the game as being purely about EDC. Big trials, she suggests, pose larger technical challenges than just gathering clinical data. “I think it will be a different game,” says Gaves. “We’re talking about a full health science and clinical development safety suite. There will be options around which applications to use.” On the EDC front, she acknowledges that an early version of the company’s solution may have been a bit too dependent on the Acrobat PDF interface from Adobe . But subsequent updates have freshened the product, adding a more traditional web-only browser interface. Oracle’s EDC software continues to be seamlessly integrated with a full-fledged clinical data management system (CDMS) in ways that other EDC solutions are not. Big pharma understands the ongoing relevance of a full-featured CDMS, Gaves says. New Unit Without tipping her hand, Gaves says there are discussions at Oracle which will convince the industry that the company is serious about offering modern, up-to-date eclinical tools. “There are things that are going on here. They’re interesting,” she says. Last June, she alerted us, Oracle created a dedicated business unit for the life sciences, something that the Redwood Shores, California company doesn’t do casually. (Here’s a release on the topic.) The new group will have additional resources and a bit of independence from the usual corporate encumbrances. (Other business units at Oracle are devoted to financial services, retail stores and insurance.) Business unit status raises the stakes. Within Oracle, there’s an expectation that the unit will be first in its industry niche. (Any such assertion about its dominance of eclinical or even EDC would be vigorously contested by Oracle’s competitors.) Says Gaves: “With that attention comes opportunity and risk and expectation. We’ve seen a lot of momentum in terms of strategic deals. It’s an extremely busy road map.” Gaves reports to Nick Giannasi, who is leading the product strategy of the business unit and a veteran of the health care division of take-no-prisoners GE . Although not typical in the eclinical space at the moment, the ability to address health care and industry-sponsored pharmaceutical research in the same product suite could be an advantage for Oracle in an era in which some customers want more all-encompassing solutions that touch both worlds. The company’s core strength in databases and their accessories remains razor-sharp. Analytics Push An example. Oracle had a clinical data repository that limped along for a while, not so much on its merits but because of perceptions that no one in any industry really ever gets much done with a data warehouse. But then a few life science customers started using Oracle’s product, and it worked. “Some customers use it to automate clinical study reports. It’s starting to take off. There are five customers up on it now and lots of interest,” Gaves reports. She offered a hint about another initiative for 2009: business intelligence. “That is the next product we’re working on,” Gaves says. Oracle did buy Hyperion and Siebel during its acquisition spree but has also put its own business intelligence mojo into the new product’s functionality. Gaves is not arrogant. “We did lose market share,” she says. But she believes the work Oracle was doing on its pharmaceutical-industry product suite leaves it well-positioned for the next few years. Says Gaves: “There are some positive things coming out of the investments we made in that time. We’re here, we’re curious.”
http://www.clinpage.com/article/oracle_buys_phase/C22 Oracle Buys Phase APRIL 26, 2010 Comments Tell a Friend Print OmniComm , a provider of electronic data capture (EDC), announced quarterly financial results. Without releasing specific revenue or profit numbers, the company said new contract awards were up 162 percent. Graham Nicholls will join Almac as director of biostatistics. After a career at GSK and Parexel, he’ll be working in the firm’s clinical technology division. “Graham brings considerable experience in adaptive trial designs, covariate adaptive (dynamic) randomization techniques, and other complex trial designs,” the release states. Bio-Optronics has updated its clinical trial management system (CTMS). The new version was refined for contract research organizations and site management organizations “to facilitate patient recruitment, study execution, regulatory compliance, financial management and communication across clinical research entities,” the release states. U.S. politicians are wading into a scientific debate over Avandia, GSK's diabetes blockbuster. Washington is trying to nudge regulators to halt a post-marketing study. One issue is the informed consent paperwork in the project. If the study is halted, it could affect whether the diabetes blockbuster remains on the market. The Wall Street Journal broke the story and unearthed this letter from the FDA to a top farm-state lawmaker. Charles River will make a major purchase in China, buying WuXi AppTec for $1.6 billion. WuXi has approximately 4,000 employees and specializes in central lab and manufacturing services. In the deal of the decade, Oracle bought Phase Forward for $685 million. The transaction is presumably under antitrust review. The purchase instantly raises Oracle’s life science profile in three key areas—electronic data capture, drug safety and randomization—after years of also-ran status. Phase Forward didn't invent EDC, but the firm did figure out how to deliver an uproven technology to a skeptical market. Phase Forward proved that EDC could be both a) profitable and b) heavily customized to the exacting specifications of big pharma. Phase Forward was able to sign large, prominent customers like GSK and Lilly to long-term contracts that gave the firm an aura of invincibility. The purchase is a tacit acknowledgment that Oracle’s own EDC product, developed with and for Pfizer, had never attracted any other admirers, even though the software was often given away. Oracle is not replying to media requests for interviews; Phase Forward canceled its usual quarterly call with Wall Street analysts. The deal is a win for Phase Forward investors, but there may be cultural issues in integrating the two firms that Oracle has not previously encountered. This January, 2009 ClinPage story is a rare case of Oracle articulating its strategy; in that story, a life sciences executive vowed that her newly reorganized business unit would grab the top position in the eclinical industry. Have a news release? Send it to us.
http://www.appliedclinicaltrialsonline.com/oracle-and-phase-forward Oracle and Phase Forward Apr 28, 2010 By Lisa Henderson Applied Clinical Trials With the announced intention to acquire Phase Forward and finalize the transaction in mid-2010, Oracle has made what one industry expert called “an interesting and daring move.” And another called it the deal of the decade . Most in the IT and financial press are “bullish” on the announcement. Most also outline Oracle’s strategy since 2005 to grow its vertical markets through acquisition, and its Health Sciences unit is no exception. Perennial acquisition began with Siebel’s Customer Relationship Management (CRM) in 2005, which sowed the seeds for an application that crossed many of Oracle’s vertical markets, and made inroads to Siebel’s existing customer base. Somewhere in there, the Siebel CTMS product along with its RDC product went into the Oracle applications mix for Life Sciences. In June 2008, Oracle created the Health Sciences business unit. The next acquisition for Oracle was the Relsys drug safety and risk management application in March 2009. Phase Forward, founded in 1997 by Paul Bleicher, MD, and while starting off with a strong EDC product for clinical trials, is no stranger to purchasing technologies. Its acquisition list includes: 2005, Lincoln Technologies, safety. October 2007, Green Mountain Logic, Phase I trials software. September 2008, Clarix Web-integrated IRT. 2009, Waban Software, automation and compliance of clinical data analysis and reporting. July 2009, Maaguzi, ePRO and late phase. August 2009, Covance’s IVR/IWR services business. Other services that comprise an end-to-end eClinical suite, besides the previously mentioned, are: CDMS, data repository, thesaurus management, FDA submissions management, and CRO management. Oracle had six of the 11; Phase Forward, 11 of 11. So there will be overlap of applications. Reports say that Oracle gains access to over 300 established Phase Forward customers. For now, there is nothing to do but wait, and speculate. Business Models Jim DeSanti, CEO of PharmaVigilant, an eClinical software provider in Westborough, Mass., said of the companies’ disparate business models: “Oracle has no ASP arm, only IT. And Phase Forward has a hybrid technology and ASP model, which was growing more on the services side the past two years. So much so that people considered it in competition with CROs.” DeSanti said that merging these two different business models would not be easy. “Clients make decisions based on certain criteria. Oracle is traditionally IT and Phase Forward, clinical.” DeSanti said the goal of IT is how to best integrate its system with the various other systems it has. The goal of clinical? To find the best tools possible to get the drug through the trial. “For them, it’s all about drug development. There are two different agendas,” he noted. In addition to that mix, throw in the overall conservativeness of the pharmaceutical industry, one that is risk averse. DeSanti remarked that the next 12 to 24 months will be an interesting one for this merger. Pricing “It'll be interesting to see how pricing goes with Oracle. I think this merger makes a lot of sense for them from a business perspective, and really puts the squeeze on smaller players migrating away from Oracle due to cost,” said Timothy Pratt, PhD, MBA, principal, Crucial Clinical and business Consultants and Editorial Advisory Board member to Applied Clinical Trials. While Pratt echoes what others have said about Oracle prior to this announcement—that Oracle is too big and too expensive for viability among the smaller to mid-size pharm or biotech—Ruchi Mallya, Analyst, Pharmaceutical Technology, Ovum told Applied Clinical Trials that she believes that this merger gives small biotech access to Oracle, not further exclusion. “Oracle would like to provide more access to their solutions. By purchasing Phase Forward and its SasS model, it offers small biotech the opportunity to have that Oracle brand. They are moving toward everyone, not just pharma.” In this article , Mallya noted that the first thing Oracle would need to address is ambiguity among clients, as well as the industry at large consisting of potential clients currently evaluating their eClinical solutions. “There is overlap of products, and so they have to clarify if they will switch over to one product, sustain both, or offer a hybrid.” While Oracle did offer letters to customers on this Web site , this blog offers advice for current customers. It also mentioned that Oracle traditionally raises its maintenance pricing by 22%. Drug Safety As mentioned, one area of overlap is drug safety. Not only did Oracle purchase a well-known provider of data safety and risk management in the form of Relsys last year, it is acquiring Phase Forward’s Empirica suite of safety solutions from clinical trials signal detection, to pharmacovigilance (originating from the Lincoln Technologies acquisition) to adverse event reporting. Sentrx, a Little Falls, NJ-based company that provides pharmacovigilance services for all aspects of drug development, in areas comprising technology, quality, medical affairs, and regulatory, also as a Business Partner, supports the safety systems provided by Oracle and Phase Forward. Sentrx CEO Chuck Saldarini told Applied Clinical Trials that he is bullish on the announcement. “We think it sends a major signal on the importance of safety,” said Saldarini. “Oracle is basically saying that safety is critical.” Saldarini outlined the current momentum within health care, specifically EMRs, the move toward a PC in every examination room to now tablet-based technologies, and how it will change the way that safety information is collected, reported, aggregated, and used within the postmarket domains, as well as how it crosses over into the clinical domain. “It’s all exciting for us,” said Saldarini. “We get access to Oracle’s expertise. And we get to track with our customers on the overall Oracle roadmap.” Medidata Then there were two--Oracle and Medidata. There are more than two, there are a host of other eClinical players who are viable and have long histories, and satisfied customers in the industry. However, the top three for some time have been Phase Forward, Medidata, and Oracle. According to Mallya, Medidata is in a unique position to differentiate itself even more from the pack. “They can say, ‘We’re an eClinical provider and we’re not a big giant.’” Medidata has its own unique history and was founded in 1999. It completed its IPO in June 2009, and currently maintains a customer base of 173. Revenues generated from customers in Europe and Asia comprise approximately one-third of its total revenues.
1. oracle客户端配置完毕。 2. 在控制面板—管理工具—数据源(ODBC) 系统DSN添加：下a c可任意取名。 a. Data source name-为stats（oracle对象之一） b. TNS Service name-为识别oracle字符串名 c. User id-用户名 3. Test connnection Service name - 默认刚才设置b User name - 默认刚才设置c Password - 库名的密码 （可以每一个库都设置一个） 4. 打开R软件 输入 conn -odbcConnect("fclub",uid="**",pwd="**") a-sqlQuery( conn ,'select * from fc_region where region_type=1') 5. 在connect情况下，无法再次connect其他对象，需要关闭当前连接 odbcClose( conn )
NEW HAVEN, CONN. (SatireWire.com) — In one of the more controversial commencement addresses in memory, Oracle CEO and college dropout Larry Ellison told Yale's Class of 2000 they were "losers" whose hard-won diplomas would never propel them into the ranks of the super rich. The evangelical Ellison, noting that college dropouts Bill Gates, Paul Allen, and Michael Dell were, like himself, on Forbes' recent top 10 list of billionaires, urged freshmen and sophomores at the ceremony to "drop out and start up," and added that the undereducated Yale security guards who ushered him off stage probably had a better shot at uber-wealth than graduating seniors. What follows is a transcript of the speech delivered by Ellison at the Yale University last month: "Graduates of Yale University, I apologize if you have endured this type of prologue before, but I want you to do something for me. Please, take a good look around you. Look at the classmate on your left. Look at the classmate on your right. Now, consider this: five years from now, 10 years from now, even 30 years from now, odds are the person on your left is going to be a loser. The person on your right, meanwhile, will also be a loser. And you, in the middle? What can you expect? Loser. Loser hood. Loser Cum Laude. "In fact, as I look out before me today, I don't see a thousand hopes for a bright tomorrow. I don't see a thousand future leaders in a thousand industries. I see a thousand losers. "You're upset. That's understandable. After all, how can I, Lawrence 'Larry' Ellison, college dropout, have the audacity to spout such heresy to the graduating class of one of the nation's most prestigious institutions? I'll tell you why. Because I, Lawrence "Larry" Ellison, second richest man on the planet, am a college dropout, and you are not. "Because Bill Gates, richest man on the planet -- for now, anyway -- is a college dropout, and you are not. "Because Paul Allen, the third richest man on the planet, dropped out of college, and you did not. "And for good measure, because Michael Dell, No. 9 on the list and moving up fast, is a college dropout, and you, yet again, are not. "Hmm... you're very upset. That's understandable. So let me stroke your egos for a moment by pointing out, quite sincerely, that your diplomas were not attained in vain. Most of you, I imagine, have spent four to five years here, and in many ways what you've learned and endured will serve you well in the years ahead. You've established good work habits. You've established a network of people that will help you down the road. And you've established what will be lifelong relationships with the word 'therapy.' All that of is good. For in truth, you will need that network. You will need those strong work habits. You will need that therapy. "You will need them because you didn't drop out, and so you will never be among the richest people in the world. Oh sure, you may, perhaps, work your way up to No. 10 or No. 11, like Steve Ballmer. But then, I don't have to tell you who he really works for, do I? And for the record, he dropped out of grad school. Bit of a late bloomer. "Finally, I realize that many of you, and hopefully by now most of you, are wondering, 'Is there anything I can do? Is there any hope for me at all?' Actually, no. It's too late. You've absorbed too much, think you know too much. You're not 19 anymore. You have a built-in cap, and I'm not referring to the mortar boards on your heads. "Hmm... you're really very upset. That's understandable. So perhaps this would be a good time to bring up the silver lining. Not for you, Class of '00. You are a write-off, so I'll let you slink off to your pathetic $200,000-a-year jobs, where your checks will be signed by former classmates who dropped out two years ago. "Instead, I want to give hope to any underclassmen here today. I say to you, and I can't stress this enough: leave. Pack your things and your ideas and don't come back. Drop out. Start up. "For I can tell you that a cap and gown will keep you down just as suredly as these security guards dragging me off this stage are keeping me dow..."
标签: Oracle经管大学堂：名校名师名课
京公网安备 11010802022788号
论坛法律顾问：王进律师
知识产权保护声明
免责及隐私声明
